BiotechTube

Lonapegsomatropin + Somatropin

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Turner Syndrome

Conditions

Turner Syndrome

Trial Timeline

Feb 15, 2023 → Dec 1, 2027

NCT ID
NCT05690386

About Lonapegsomatropin + Somatropin

Lonapegsomatropin + Somatropin is a phase 2 stage product being developed by Ascendis Pharma for Turner Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT05690386. Target conditions include Turner Syndrome.

What happened to similar drugs?

3 of 8 similar drugs in Turner Syndrome were approved

Approved (3) Terminated (0) Active (5)
✅HumatropeEli LillyApproved
✅r-hGHMerckApproved
✅estradiolNovo NordiskApproved
🔄SomatropinEli LillyPhase 3
🔄17 beta estradiolEli LillyPhase 3
🔄Somatropin + Ethinyl estradiol + Medroxyprogesterone acetateEli LillyPhase 3
🔄Somapacitan + Norditropin®Novo NordiskPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05690386Phase 2Active
NCT04615273Phase 3Completed

Competing Products

10 competing products in Turner Syndrome

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
40
HumatropeEli LillyApproved
43
17 beta estradiolEli LillyPhase 3
40
Somatropin + Ethinyl estradiol + Medroxyprogesterone acetateEli LillyPhase 3
40
r-hGHMerckApproved
43
Somapacitan + Norditropin®Novo NordiskPhase 3
44
estradiolNovo NordiskApproved
43
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patchNovo NordiskPhase 1
21
somatotropinPfizerPre-clinical
26
Somatropin (rDNA origin)IpsenPhase 3
37